PMID- 31855919 OWN - NLM STAT- MEDLINE DCOM- 20210624 LR - 20240211 IS - 1935-3227 (Electronic) IS - 1932-0620 (Print) IS - 1932-0620 (Linking) VI - 14 IP - 4 DP - 2020 Jul/Aug TI - Common and Challenging Behaviors Among Individuals on Long-term Opioid Therapy. PG - 305-310 LID - 10.1097/ADM.0000000000000587 [doi] AB - OBJECTIVE: Long-term opioid therapy (LTOT) is commonly prescribed for chronic pain, despite risks such as opioid use disorder (OUD) and overdose. Caring for patients on LTOT can be difficult, given lack of evidence about assessment of challenging behaviors among patients on LTOT. To develop this evidence, a critical first step is to systematically identify the common and challenging behaviors that primary care providers encounter among patients on LTOT, and also to highlight to diverse range of behaviors encountered. METHOD: We conducted a Delphi study in 42 chronic pain experts to determine consensus on how to address the top common and challenging behaviors. This paper reports on the first round of the study, which elicited a range of behaviors. We conducted thematic analysis of the behaviors and also used the Diagnostic and Statistical Manual (DSM)-5 criteria for OUD as a priori codes. RESULTS: In all, 124 unique behaviors were identified by participants and coded into 4 thematic categories: concerning behaviors that map onto DSM-5 criteria for OUD, and those that do not which were: behaviors that suggest deception, signs of diversion, and nonadherence to treatment plan. Those behaviors that fell outside of OUD criteria we identified as "gray zone" behaviors. CONCLUSIONS: While some of these challenging behaviors fall under the criteria for an OUD, many fall outside of this framework, making diagnosis and treatment difficult, and consensus on how to deal with these "gray zone" behaviors is vital. Future research should explore how these "gray zone" behaviors can best be assessed and managed in a primary care setting. FAU - Young, Sarah R AU - Young SR AD - Department of Social Work, College of Community and Public Affairs, Binghamton University, Binghamton, NY (SRY); University of California, San Francisco, CA (SA); VA Connecticut Healthcare System, West Haven, CT (WCB); Yale School of Medicine, New Haven, CT (WCB, EJE); University of Pittsburgh Department of Medicine, Pittsburgh, PA (JML, JSM); Boston Medical Center, Boston University School of Medicine, Boston, MA (PR); Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (JLS). FAU - Azari, Soraya AU - Azari S FAU - Becker, William C AU - Becker WC FAU - Edelman, E Jennifer AU - Edelman EJ FAU - Liebschutz, Jane M AU - Liebschutz JM FAU - Roy, Payel AU - Roy P FAU - Starrels, Joanna L AU - Starrels JL FAU - Merlin, Jessica S AU - Merlin JS LA - eng GR - K23 MH104073/MH/NIMH NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - K12 DA033312/DA/NIDA NIH HHS/United States GR - K23 DA027719/DA/NIDA NIH HHS/United States GR - K24 DA046309/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - Netherlands TA - J Addict Med JT - Journal of addiction medicine JID - 101306759 RN - 0 (Analgesics, Opioid) SB - IM MH - Analgesics, Opioid/adverse effects MH - *Chronic Pain/drug therapy MH - Diagnostic and Statistical Manual of Mental Disorders MH - *Drug Overdose/drug therapy MH - Humans MH - *Opioid-Related Disorders/drug therapy PMC - PMC7297656 MID - NIHMS1540868 EDAT- 2019/12/20 06:00 MHDA- 2021/06/25 06:00 PMCR- 2021/07/01 CRDT- 2019/12/20 06:00 PHST- 2019/12/20 06:00 [pubmed] PHST- 2021/06/25 06:00 [medline] PHST- 2019/12/20 06:00 [entrez] PHST- 2021/07/01 00:00 [pmc-release] AID - 10.1097/ADM.0000000000000587 [doi] PST - ppublish SO - J Addict Med. 2020 Jul/Aug;14(4):305-310. doi: 10.1097/ADM.0000000000000587.